TXinno Bioscience Inc.

TXinno Bioscience is a South Korean biotechnology company founded in 2020 that specializes in developing innovative low-molecular-weight cancer therapeutics. The company focuses on two primary areas: (1) tumor-intrinsic factors targeting RAS signaling pathways through ULK1 inhibitors, and (2) tumor-extrinsic factors targeting innate immunity through ENPP1 inhibitors that activate the STING signaling pathway. TXinno's platform includes proprietary technologies such as the Ba/F3 kinase evaluation system for discovering kinase target drugs with tumor mutations. The company is advancing its lead candidate TXN10128, an orally bioavailable ENPP1 inhibitor, through Phase 1 clinical trials as a single agent and in combination with chemotherapy in patients with locally advanced or metastatic solid tumors. TXinno's strategic focus combines immunotherapy (STING pathway activation) with targeted cancer therapy (RAS-mutated cancers) to address unmet medical needs in oncology.